These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 31559852

  • 41. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.
    Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
    [Abstract] [Full Text] [Related]

  • 42. Tiotropium/Olodaterol: A Review in COPD.
    Dhillon S.
    Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. [Spiolto Respimat® : tiotropium-olodaterol fixed combination for therapy of chronic obstructive pulmonary disease (COPD)].
    Cataldo D.
    Rev Med Liege; 2016 Jun; 71(6):308-313. PubMed ID: 28383865
    [Abstract] [Full Text] [Related]

  • 45. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
    Stanford RH, Parker ED, Reinsch TK, Buikema AR, Blauer-Peterson C.
    Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
    [Abstract] [Full Text] [Related]

  • 46. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS, Landis SH, Wurst K, Le H.
    Respir Res; 2015 Nov 16; 16():141. PubMed ID: 26572740
    [Abstract] [Full Text] [Related]

  • 47. First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease.
    Takahashi K, Uchida M, Kato G, Takamori A, Kinoshita T, Yoshida M, Tajiri R, Kojima K, Inoue H, Kobayashi H, Sadamatsu H, Tashiro H, Tanaka M, Hayashi S, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T, Saga-naïve COPD Physical Activity Evaluation (SCOPE) Study Investigator Group.
    Int J Chron Obstruct Pulmon Dis; 2020 Nov 16; 15():2115-2126. PubMed ID: 32982204
    [Abstract] [Full Text] [Related]

  • 48. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.
    Kwak MS, Kim E, Jang EJ, Kim HJ, Lee CH.
    Int J Chron Obstruct Pulmon Dis; 2015 Nov 16; 10():2365-76. PubMed ID: 26604734
    [Abstract] [Full Text] [Related]

  • 49. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO®/DYNAGITO® Trials.
    Wedzicha JA, Buhl R, Singh D, Vogelmeier CF, de la Hoz A, Xue W, Anzueto A, Calverley PMA.
    Adv Ther; 2020 Oct 16; 37(10):4266-4279. PubMed ID: 32776202
    [Abstract] [Full Text] [Related]

  • 50. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
    Melani AS.
    Expert Opin Pharmacother; 2018 Oct 16; 19(14):1603-1611. PubMed ID: 30311516
    [Abstract] [Full Text] [Related]

  • 51. Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD.
    Manoharan A, Morrison AE, Lipworth BJ.
    Lung; 2016 Apr 16; 194(2):259-66. PubMed ID: 26758884
    [Abstract] [Full Text] [Related]

  • 52. Switching from long-acting beta-agonist and inhaled corticosteroid to long-acting beta-agonist and long-acting muscarinic antagonist for chronic obstructive pulmonary disease: a case report of inhaled corticosteroid withdrawal.
    Lam JCM.
    Intern Med J; 2020 Sep 16; 50 Suppl 3():15-18. PubMed ID: 32985094
    [Abstract] [Full Text] [Related]

  • 53. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016 Sep 16; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

  • 54. Effects of Tiotropium/Olodaterol on Activity-Related Breathlessness, Exercise Endurance and Physical Activity in Patients with COPD: Narrative Review with Meta-/Pooled Analyses.
    Maltais F, de la Hoz A, Casaburi R, O'Donnell D.
    Adv Ther; 2021 Feb 16; 38(2):835-853. PubMed ID: 33306188
    [Abstract] [Full Text] [Related]

  • 55. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
    Nielsen R, Kankaanranta H, Bjermer L, Lange P, Arnetorp S, Hedegaard M, Stenling A, Mittmann N.
    Respir Med; 2013 Nov 16; 107(11):1709-21. PubMed ID: 23856511
    [Abstract] [Full Text] [Related]

  • 56. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD.
    Weng CF, Wu CC, Wu MH, Lin FJ.
    Chest; 2023 Apr 16; 163(4):799-814. PubMed ID: 36442662
    [Abstract] [Full Text] [Related]

  • 57. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database.
    Calabria S, Ronconi G, Dondi L, Piccinni C, Pedrini A, Esposito I, Pistelli R, Martini N.
    Pulm Pharmacol Ther; 2020 Apr 16; 61():101904. PubMed ID: 32092473
    [Abstract] [Full Text] [Related]

  • 58. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting.
    Bogart M, Glassberg MB, Reinsch T, Stanford RH.
    Respir Med; 2018 Dec 16; 145():138-144. PubMed ID: 30509702
    [Abstract] [Full Text] [Related]

  • 59. Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort.
    Busch R, Han MK, Bowler RP, Dransfield MT, Wells JM, Regan EA, Hersh CP, COPDGene Investigators.
    BMC Pulm Med; 2016 Feb 10; 16():28. PubMed ID: 26861867
    [Abstract] [Full Text] [Related]

  • 60. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.
    Nagar S, Patel J, Stanford RH.
    Manag Care; 2018 May 10; 27(5):40-47. PubMed ID: 29763411
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.